UFP Technologies Inc. filings document operating results and material events for its medical-device contract development and manufacturing business. Form 8-K reports furnish quarterly and annual earnings releases, non-GAAP financial measures, Regulation FD investor presentation materials, material definitive agreements with strategic medical customers, cybersecurity incident disclosures, and executive succession and compensation arrangements.
Proxy filings cover board elections, executive compensation, equity awards, pay-versus-performance disclosure, and shareholder voting matters. These records frame the company's governance, capital and incentive structure, customer-contract disclosures, and public reporting obligations as a Nasdaq-listed operating company.
UFP Technologies, Inc. (UFPT) reported third-quarter net sales of $172.4 million, up 11.6% from $154.6 million a year earlier, and net income of $20.6 million versus $16.4 million. Gross margin was 29.4%, compared with 27.7%. For the first nine months, net sales were $500.6 million, up 10.3%, organic sales growth was 7.9%, and net income was $59.0 million versus $50.7 million.
Nine-month cash provided by operations was $57.4 million, compared with $75.1 million a year earlier. Management attributed the cash flow in part to approximately $28.9 million of changes in operating assets and liabilities, primarily a $13.7 million increase in net receivables associated with higher third-quarter sales volume.
UFP Technologies purchased 100% of CI Medical on August 25, 2026, for an aggregate purchase price of $6.9 million in cash, subject to adjustment based on estimated working capital at closing. At September 30, outstanding borrowings were $96.0 million, the weighted average interest rate was 5.2%, and the company reported compliance with its financial covenants.
UFP Technologies reported third-quarter net sales of $172.4 million, up 11.6% from $154.6 million, and net income of $20.6 million, up 25.8% from $16.4 million, for the quarter ended September 30, 2026. Organic sales growth was 11.1%. GAAP diluted EPS was $2.64, while adjusted diluted EPS was $2.88. Gross margin rose to 29.4% from 27.7%.
Adjusted operating income increased 14.5% to $30.1 million and adjusted EBITDA increased 15.3% to $35.4 million. For the first nine months, sales were $500.6 million, up 10.3%, and net income was $59.0 million, up 16.2%; adjusted EBITDA was $102.8 million, up 10.7%. Third-quarter SG&A rose 21.4% to $23.2 million, or 13.4% of sales versus 12.3%. Management said Dominican Republic program transfers and margin improvement remained behind plan, and said it was working to expand its credit facility while making progress on acquisition opportunities.
UFP Technologies Inc. (UFPT) is the issuer in Wasatch Advisors’ Amendment No. 4 ownership report, which lists 552,809 common shares beneficially owned, or 7.1% of the class. Wasatch reported sole voting power over 363,292 shares and sole dispositive power over 552,809 shares; shared voting and dispositive power were both zero.
UFP TECHNOLOGIES INC (UFPT) director Marc D. Kozin reported selling a total of 7,000 shares of common stock on 2026-08-25 in two open-market or private transactions. The reported per-share prices are weighted averages over price ranges, and post-transaction share holdings are not stated in this filing.
UFP Technologies Inc. (UFPT) disclosed a planned sale of 7,000 shares of common stock under Rule 144 for the account of director Marc D. Kozin, with shares held in the Marc D. Kozin Revocable Trust U/A 7/28/23 and to be sold through Fidelity Brokerage Services. The notice lists an aggregate market value of $2,140,950.00 for these shares. The shares derive from stock awards granted between 2019 and 2023 totaling 3,258 shares, with specified vesting dates from 2020 to 2024. Shares outstanding are shown as 7,713,300, a baseline figure, not the amount being sold.
UFP Technologies, Inc. (UFPT) furnished updated investor presentation materials describing its MedTech-focused contract development and manufacturing business and multi-year performance. The company positions itself as a partner for medical device and sterile packaging solutions, serving large OEMs, niche device makers, and start-ups across six countries with more than 5,000 team members.
The presentation highlights revenue of $603 million in 2025, up from $179 million in 2020, with a reported 3.4× revenue growth over that period. Adjusted operating margin is shown rising from 10.0% in 2020 to 17.1% in 2025, and the company reports 29.0% gross margin and 17.2% adjusted operating margin year-to-date through June 30, 2026. As of August 17, 2026, the presentation states a market capitalization of approximately $2.5 billion.
Management outlines 3–5 year financial targets of 12–18% annual revenue growth, 28–31% gross margins, and 17–20% adjusted operating margins, supported by an organic growth and customer-centric M&A strategy focused on higher-growth medical segments such as robotic assisted surgery, infection control, cardiovascular, and wound care.
UFP Technologies Inc (UFPT) director Symeria Hudson reported an open-market sale of the company’s common stock. The transaction involved 298 shares of Common Stock, $.01 par value, sold on 2026-08-18 at a price of $319.11 per share. After this sale, Hudson directly holds 927 shares of UFP Technologies common stock.
UFP Technologies director Symeria Hudson reported option-related trades in Common Stock. On August 13, 2026, Hudson exercised stock options covering 703 shares at an exercise price of $167.98 per share and 493 shares at $260.92 per share, acquiring the same number of common shares. On August 14, 2026, Hudson sold 1,926 common shares in open-market or private transactions at a weighted average price of $324.58 per share, with individual sale prices ranging from $324.36 to $324.945.
Director Cynthia L. Feldmann sold 1,000 shares of UFP Technologies (UFPT) Common Stock, $.01 Par Value on 2026-08-13 in a sale classified as an open market or private transaction at $324.26 per share. Following this transaction, she directly holds 4,476 shares of UFPT common stock.
UFP Technologies, Inc. board member Symeria Hudson filed an amended notice of a proposed sale of 2,224 common shares, with an aggregate market value of $625,145.67 and an approximate sale date of August 14, 2026. The listed shares were acquired from the issuer through stock option exercises (703 shares acquired June 7, 2023, and 493 shares acquired June 5, 2024) and stock awards (230 shares on June 2, 2025, 500 shares on June 1, 2026, and 298 shares on May 31, 2024). Merrill Lynch is listed as the broker.